Two Unconventional Yet Effective Paths to Differentiation

Posted by Josh Hattem on Fri, Jan 24, 2020

Emily Mandell co-wrote this blog post with Josh Hattem.

With the return on development investment declining in pharma, product differentiation is more important than ever. In our last two blog posts, we explained the challenges surrounding product differentiation and shared four potential paths to clinical differentiation. Here we explore the final two – and most unconventional – paths to differentiation: solving a different problem and building a different yardstick.

Read More